Breaking News Instant updates and real-time market news.

VCYT

Veracyte

$7.59

0.01 (0.13%)

17:36
10/17/16
10/17
17:36
10/17/16
17:36

Veracyte reports preliminary Q3 EPS (20c)-(21c), consensus (39c)

Reports preliminary Q3 revenue $18.6M, consensus $15.72M.

  • 29

    Nov

VCYT Veracyte
$7.59

0.01 (0.13%)

06/28/16
COWN
06/28/16
NO CHANGE
Target $8
COWN
Outperform
Cowen surprised Anthem still considers Veracyte's Afirma investigational
Cowen analyst Doug Schenkel noted that a new Anthem (ANTM) medical policy on thyroid nodule testing went into effect today, in which the insurer stated that it still considers Veracyte's (VCYT) Afirma GEC test "investigational and not medically necessary". The updated medical policy is a bit of a "surprising disappointment," said Schenkelm, though he added that the new policy "clearly does not consider some newer data." Veracyte's management is still optimistic that Anthem will issue a positive coverage decision, which could still occur in 2016, according to Schenkel, who has an Outperform rating and $8 price target on Veracyte shares.
07/07/16
PIPR
07/07/16
NO CHANGE
PIPR
New FDA recommendation positive for lab companies, says Piper Jaffray
Piper Jaffray analyst William Quirk says that the FDA has issued draft guidance to streamline its approval process for next-generation sequencing, or NGS, germline tests, which could be a substitute for a Premarket Notification or 510k. The analyst believes streamlined regulatory approaches for NGS tests are a positive for labs with NGS laboratory-developed tests such as CareDx (CDNA), Quest Diagnostics (DGX), Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA), Oxford Immunotec (OXFD), Sequenom (SQNM), Trovagene (TROV), and Veracyte (VCYT).
08/04/16
SPHN
08/04/16
NO CHANGE
Target $9
SPHN
Overweight
Veracyte price target lowered to $9 from $14 at Stephens
Stephens analyst Drew Jones lowered his price target for Veracyte to $9 from $14 on valuation after the company reported Q2 revenue in line with expectations. Looking ahead, the analyst believes the company remains on track with its pulmonology pipeline. Jones reiterates an Overweight rating on the shares.
09/08/16
CANT
09/08/16
NO CHANGE
Target $13
CANT
Buy
Cantor says buy Veracyte following draft local coverage determination
Cantor analyst Bryan Brokmeier recommends that investors buy shares of Veracyte following the announced draft local coverage determination, or LCD, for the company's Percepta Bronchial Genomic Classifier. The analyst says this draft LCD with Noridian Healthcare Solutions represents over 30M covered lives for its Percepta and represents more than 25% of the U.S. market opportunity. Further, Brokmeier believes other Medicare Administrative Contractors will follow Noridian's lead. The analyst reiterates a Buy rating and $13 price target on the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.